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100,000 cells, and after stimulation with LPS, it was 403 88 (n
28, adjusted to 100%). The addition of 10% irradiated human
MSCs gave 76  9%. Despite this suppression of IgG secretion,
we saw high variations in the experiments, as well as increased IgG
secretion. Stimulation with CMV gave a median of 330  98
SFU/100,000 cells (n  3), and the addition of 10% MSCs to the
culture reduced the response to 150  63. Stimulating spleen cells
with VZV gave 830 SFC/100,000 cells, which was reduced to 84
7 with 10% MSCs present. Enriched B cells were negatively
selected using immunomagnetic beads (Dynal, Norway). Using
enriched B cells, IgG production stimulated by LPS were variably
inhibited, unchanged, or stimulated after addition of 10% MSCs in
the culture, giving an average of increased IgG production (170 
53% compared with 100% in the positive control; n  5). Varia-
tions between different MSCs were similar to those using crude
spleen cells, indicating that MSCs most likely have a direct effect
on B cells, but because there might be some contaminating T cells
remaining in the culture (ﬂow cytometry showed  0.5% T cells),
we can not rule out that MSCs inhibit T cells and then in-direct
the B cells. When T cells are activated in mixed lymphocyte
cultures or by phytohemagglutinin, MSCs in high concentrations,
10% to 40% in the culture, mainly inhibit proliferation, whereas
low concentrations, 1%, in some experiments enhance lymphocyte
proliferation. For IgG secretion induced by LPS and viral antigens
CMV or VZV, 10% MSCs in culture inhibits IgG secretion in
most experiments, although a high variation in responses is seen
with this concentration. To conclude, MSCs inhibited B-cell IgG
secretion by human spleen cells induced by CMV and VZV.
However, induction by LPS on crude spleen cells or puriﬁed B
cells mainly stimulated IgG production.
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DURABLE ENGRAFTMENT OF AMD3100-MOBILIZED HEMATOPOIETIC
STEM CELLS IN A CANINE AUTOLOGOUS AND ALLOGENEIC MODEL
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AMD3100 is a synthetic molecule that inhibits binding of stro-
mal cell–derived factor-1 to its receptor, CXCR4, expressed on
hematopoietic cells. AMD3100 treatment of animals or humans
results in mobilization of hematopoietic progenitor cells. Periph-
eral blood mononuclear cells (PBMCs) mobilized with a combina-
tion of AMD3100 plus G-CSF stably reconstituted autologous
hematopoiesis in cancer patients following myeloablative condi-
tioning. However, the engraftment potential of AMD3100-PBMC
used alone has remained unproven. We therefore studied this
potential in the autologous and DLA-identical littermate canine
hematopoietic cell transplantation (HCT) models. Pharmacoki-
netic studies performed in 4 dogs given a single dose of AMD3100
(4 mg/kg SC) demonstrated a 3- to 10-fold increase in CD34
cells measured by ﬂow cytometry, and a 2- to 5-fold increase in
CFU-GM and BFU-E within 8–10 hours of AMD3100 adminis-
tration. For autologous HCT, 4 dogs received a single dose each of
AMD3100 (4 mg/kg) followed by 3–4 hours of leukaphereses
initiated 6–7 hours after AMD3100 administration. Thereafter,
dogs were given a single dose of myeloablative total body irradia-
tion (TBI), 920 cGy at 7 cGy/min, followed by infusion of autol-
ogous AMD3100-PBMC (median CD34 cell count, 3.9 106/kg).
Neutrophil and platelet engraftment occurred at medians of 9 days
(range, 7–10 days) and 25 days (range, 23–38 days), respectively,
after HCT. At a median follow-up of 11.5 months (range, 8–12
months), all 4 dogs had normal marrow function. Because a con-
tribution of surviving endogenous stem cells to marrow function
could not be ruled out in the autologous HCT model, we next
evaluated the engraftment potential of AMD3100-PBMC in the
allogeneic HCT model. Four dogs were given AMD3100-PBMC
(median CD34 cell count, 3.4  106/kg) from DLA-identical
littermates after conditioning with 920 cGy TBI. Postgrafting
cyclosporine (5 mg/kg twice daily) was given from days1 to35.
Neutrophil and platelet engraftment occurred at medians of 9 days
(range, 8–10 days) and 26 days (range, 26–37 days), respectively.
At a median follow-up for living recipients of 162 days (range,
72–178 days), 3 dogs were alive and demonstrated 99%-100%
donor chimerism by VNTR analysis. One dog had early evidence
of engraftment but was euthanized 18 days after HCT because of
canine HSV infection and pancreatitis. In summary, both autolo-
gous and allogeneic AMD3100-PBMC transplants were associated
with timely and durable engraftment in dogs conditioned with
myeloablative TBI.
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ALLOGENEIC T CELLS INDUCE CORD BLOOD CD34 OR CD133
CELLS RAPID PROLIFERATION AND DIFFERENTIATION INTO DEN-
DRITIC CELL PRECURSORS
Abbasian, J., Mahmud, N., Rondelli, D. Section of Hematology/Oncol-
ogy, University of Illinois at Chicago, Chicago, IL.
In this study we tested whether initial contact with allogeneic
lymphocytes may increase human cord blood (CB) hemopoietic
stem cells (HSCs) alloantigen-presenting capacity. Irradiated im-
munomagnetically puriﬁed CB CD34 and CD133 HSCs in-
duced similar proliferation (mean stimulation index, 19  5 and
16 5, respectively) of allo-responders in primary mixed leukocyte
culture (MLC). Cocultures of nonirradiated CD34 or CD133
cells with irradiated allogeneic T cells for 6 days resulted in a brisk
proliferation of HSC fractions (mean stimulation index, 17  2).
HSC proliferation was inhibited by B7:CD28 blockade with
CTLA-Ig. HSC that had been cocultured with irradiated alloge-
neic T cells for 6 days, were then rechallenged as stimulators in
MLC, and induced a signiﬁcantly greater T-cell alloresponse as
compared with the same freshly isolated HSCs (stimulation index,
134 54 vs 24 8) (P .03). The phenotypic kinetics of CD34
and CD133 CB cells on contact with irradiated T cells showed a
rapid up-regulation of CD86 within 24 hours (on average from 2%
 1% to 7%  2%, and from  1% to 4%  1%, respectively).
At 3 and 6 days of culture, both CD34 and CD133 CB cells
became larger and included a population of HLADR CD14
CD86 CD11c progenitors, on average 16%, consistent with
the phenotype of DC precursors. Also, irradiated allogeneic lym-
phocytes induced the generation of 8% CD1a DCs after 8 days
of culture with HSCs. To assess the effect of allogeneic lympho-
cytes on CB CD34 cell-derived DC generation in vivo, 10
NOD/SCID mice were irradiated (300 cGy) and injected with
0.20  106 CD34 CB cells and autologous (CD34/auto) or
allogeneic (CD34/allo) MNC (ratio 1:2), or with autologous or
allogeneic cells alone as control. At 6 weeks after transplant, mar-
row cells were harvested, and human CD45 cells were on average
1.8% in CD34/auto and 3.2% in CD34/allo. Although similar
proportions of B cells (CD45CD19) and monocytes
(CD45CD14) were detected in the two groups, a greater num-
ber of myeloid dendritic cells (CD45BDCA1) was observed
in CD34/allo than in CD34/auto (0.45%  0.30% vs 0.04% 
0.04%). These ﬁndings suggest that allogeneic lymphocytes may
induce a rapid differentiation of HSC into DC with potent alloan-
tigen-presenting capacity. Future studies aimed at either selectively
abrogating this subset of progenitors or blocking HSC:T-cell re-
ciprocal activation will be developed in the attempt of facilitating
the induction of tolerance in allogeneic HSC transplantation.
211
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Cord blood (CB) contains nonhematopoietic stem cells referred
to as mesenhymal stem cells (MSCs). These cells contained in CB
can be considered as “very young,” and thus CB may be an excel-
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